These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 26324517

  • 1. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Chen J, Zhuang X, Long M, Su C, Wang L.
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
    [Abstract] [Full Text] [Related]

  • 2. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY, ENSURE-AF investigators.
    Lancet; 2016 Oct 22; 388(10055):1995-2003. PubMed ID: 27590218
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL.
    Am J Cardiovasc Drugs; 2015 Oct 22; 15(5):351-61. PubMed ID: 26369340
    [Abstract] [Full Text] [Related]

  • 6. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH, Merino JL, Dan GA, Themistoclakis S, Ellenbogen KA, De Caterina R, Goudev A, Jin J, Melino M, Winters SM, Goette A.
    Am J Cardiol; 2018 Jan 15; 121(2):193-198. PubMed ID: 29169605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.
    Aronow WS, Shamliyan TA.
    Am J Ther; 2019 Jan 15; 26(6):e679-e703. PubMed ID: 30461433
    [Abstract] [Full Text] [Related]

  • 12. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP.
    J Am Coll Cardiol; 2019 Jul 16; 74(2):179-189. PubMed ID: 31296289
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
    O'Donoghue ML, Ruff CT, Giugliano RP, Murphy SA, Grip LT, Mercuri MF, Rutman H, Shi M, Kania G, Cermak O, Braunwald E, Antman EM.
    Eur Heart J; 2015 Jun 14; 36(23):1470-7. PubMed ID: 25687352
    [Abstract] [Full Text] [Related]

  • 17. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
    Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT.
    J Am Coll Cardiol; 2016 Sep 13; 68(11):1169-1178. PubMed ID: 27609678
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.
    Am Heart J; 2010 Oct 13; 160(4):635-41. PubMed ID: 20934556
    [Abstract] [Full Text] [Related]

  • 19. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, Silverman S, Singhal AB, Nicolau JC, SomaRaju B, Mercuri MF, Antman EM, Braunwald E, ENGAGE AF-TIMI 48 Investigators.
    Stroke; 2016 Aug 13; 47(8):2075-82. PubMed ID: 27387994
    [Abstract] [Full Text] [Related]

  • 20. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, Henderson DA, Mercuri MF, Rutman H, Antman EM, Braunwald E.
    Am Heart J; 2016 Feb 13; 172():144-51. PubMed ID: 26856226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.